跳至主要内容
临床试验/ACTRN12610000678099
ACTRN12610000678099已完成4 期

A randomised controlled trial of oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

Amgen0 个研究点目标入组 60 人开始时间: 2010年8月18日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Amgen
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.On peritoneal dialysis greater than or equal to 1 month.
  • 2.On darbepoetin for greater than or equal to 1 month
  • 3.18 years or over.
  • 4.Able to give informed consent.

排除标准

  • 1.Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study.
  • 2.Pregnancy or breast-feeding.
  • 3.Known hypersensitivity to, or intolerance of, oral iron, HIP or DPO.
  • 4.Active peptic ulcer disease.
  • 5.Vitamin B12 or folate deficiency.
  • 6.Recent (within 1 month) acute infection.
  • 7.Parathyroid hormone level greater than 100 pmol/L.
  • 8.Serum aluminium greater than 2 micromol/L.
  • 9.Presence of systemic haematological disease (including antibody-mediated pure red cell aplasia) or known haemoglobinopathy
  • 10.Major surgery, infection, acute myocardial infarction or malignancy within the last 3 months.
  • 11.Intravenous iron therapy, vitamin C therapy, melatonin treatment, androgen therapy or blood transfusion within the previous month.
  • 12.Serum ferritin greater than 500 microg/mL or transferrin saturation (TSAT) greater than 50%.
  • 13.Religious or other objection to consuming product prepared from bovine blood.

研究者

发起方
Amgen

相似试验